Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8389054 | 0.85 | CYP19A1 (0.68) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL20601860 | 0.83 | TBXAS1 (0.67) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL10662504 | 0.82 | CYP11B1 (0.64) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL11706257 | 0.81 | KDM4E (0.68) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL11702473 | 0.81 | CYP19A1 (0.80) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6057478 | 0.80 | CYP11B1 (0.68) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL8390116 | 0.80 | TBXAS1 (0.65) | TBXAS1CYP19A1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL1024261 | 0.80 | CYP11B1 (0.84) | TBXAS1CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL10852178 | 0.79 | TBXAS1 (1.00) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8390083 | 0.79 | FNTA (0.64) | TBXAS1CYP19A1CYP11B1CYP11B2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958353-B2 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | HISAMITSU MEDICAL CO., LTD. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030207896-A1 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1295880-A1 | IMIDAZOLE DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE DERIVATIVES OR THE SALTS | SSP Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-4731370-A | VASODILATOR, ANTICOAGULANT | TOYAMA CHEMICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| US-4713387-A | Vasodilating and platelet aggregation inhibiting 1,4 dihydropyridines with an imidazolyl or pyridyl containing ester | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207896-A1 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | IL6, NOS1, NOS2 | TBXAS1 626/4885CYP19A1 1205/4885CYP11B1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.